Alberta's Doctors Get a Peptide Briefing: What the CPSA's October 2026 Guidance Says

Peptides have moved from gym talk to the doctor's office. This month, the College of Physicians & Surgeons of Alberta (CPSA), the body that licenses and regulates Alberta's physicians, published a prescribing resource devoted entirely to peptide drugs. It's a clear Canadian summary of which peptides are authorized, which aren't, and why regulators are worried.

This post is a research summary for Canadian readers. It reports what regulators and published sources say. It is not medical advice, and it does not suggest that anyone buy, inject, or use any peptide.

What the CPSA published

The document is called Q3 2026 MD Snapshot-Prescribing Companion: Peptide Drugs, dated October 2026. It's written for physicians, and it opens by noting "significant public, media and commercial interest in peptide drug therapeutics in Canada."

It splits peptides into two groups that are often blurred together online.

1. Unauthorized peptides. The CPSA lists examples of injectable peptides that are not authorized for sale in Canada, based on a Health Canada advisory. They include BPC-157, TB-500, GHK-Cu, KPV, CJC-1295, ipamorelin, Semax, Selank, DSIP, retatrutide, AOD9604, Melanotan I and II, kisspeptin, and thymosin alpha-1. The College adds that the marketing claims it lists next to them (injury recovery, anti-aging, fat loss, and so on) "are not indicative of effectiveness or Health Canada approval."

2. Authorized peptides. Health Canada has approved many peptide drugs, including insulin, oxytocin, calcitonin, desmopressin, glucagon, octreotide, semaglutide, and tirzepatide. The CPSA highlights two 2026 Canadian approvals: a new Ozempic indication to reduce major cardiovascular events in some adults with type 2 diabetes, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. It also notes that several generic semaglutide products have been authorized since April 2026.

The takeaway: "peptide" describes a type of molecule, not a legal category. Some peptides are rigorously tested prescription drugs, and others have never been assessed by Health Canada at all.

Why regulators are concerned

The CPSA pulls together several warning signs.

• Product risks. Citing Health Canada, it says unauthorized injectables may contain contaminants such as "solvents, heavy metals, glass, plastic, bacteria and endotoxins." It also lists reported harms including infections, allergic reactions, liver or kidney damage, blood clots, and tumour growth.

• A real-world cluster in Australia. In June 2026, Victoria's Chief Health Officer issued an alert about six cases of acute liver toxicity since January in people who used unapproved products labelled "Retatrutide." The alert said the toxicity was "possibly associated with a contaminant" and that further testing of the products was underway. Retatrutide itself is still an investigational drug that no regulator has approved.

• A compounding gap. The CPSA points to a July 2026 CBC News hidden-camera investigation that found some doctors prescribing BPC-157 as a compounded pill. Health Canada told CBC that BPC-157 "has not been authorized, its safety, efficacy, and quality have not been assessed," and that there is "a lack of established human dosing protocols." Separately, in May 2026 Health Canada announced a Type I recall of GHK-Cu and BPC-157 powders supplied to compounding and community pharmacies, because they were unauthorized active pharmaceutical ingredients.

The College is also candid about a data gap. It says there are no reliable population-level rates of harm from unauthorized peptides in Canada, and there's "a lack of rigorous clinical research regarding the safety and efficacy of these products in humans."

What it asks Alberta doctors to do

The guidance asks physicians to talk with patients, not to prescribe these products. Doctors are asked to ask patients about non-prescribed injectables bought online, watch for complications, check Health Canada's Drug Product Database, and counsel patients not to buy unauthorized products. They're also asked to explain that legitimate products carry an eight-digit DIN or NPN, and to report adverse events to Health Canada.

Meanwhile, outside Canada

This week brought very different moves elsewhere.

• United States: On October 7, The Washington Post reported, citing two unnamed sources, that the administration is crafting plans to allow the temporary sale of certain previously restricted peptides while regulators work on new rules. A day later, Pink Sheet reported that FDA drug centre staff said they won't recommend allowing temporary compounding of unapproved peptides. None of this is an FDA approval, and none of it changes Canadian law.

• Brazil: On October 6, Brazil's health regulator, Anvisa, ordered the seizure of unregistered peptide products and banned their sale, advertising, and use. The order covered retatrutide and tirzepatide pens plus products labelled BPC-157/TB-500 and GHK-Cu. Anvisa said the products were presented as being for research but showed signs they were meant for human use.

What the evidence does and doesn't show

• Authorized peptides such as semaglutide and tirzepatide went through Health Canada's review, which for drugs like these requires human clinical trial evidence.

• Unauthorized "wellness" peptides lack rigorous human research on safety and efficacy, according to the CPSA. For BPC-157, Health Canada calls the scientific evidence "limited."

• Harm data is incomplete. Clusters like the Victoria cases are documented, but the CPSA found no reliable population-level rates of harm for Canada.

The bottom line

Canada's message has stayed consistent all year, and Alberta's physician regulator is now putting it in front of Alberta physicians. Unauthorized peptides haven't been assessed for safety, quality, or effectiveness. A "research use only" label doesn't make them legal to sell for human use, and the science behind most of them is still at the lab stage.

Sources

• College of Physicians & Surgeons of Alberta. Q3 2026 MD Snapshot-Prescribing Companion: Peptide Drugs (October 2026)

• Health Canada. Think twice before injecting peptides bought online (April 9, 2026)

• Health Canada. GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients (May 7, 2026)

• CBC News. Doctors are using a regulatory gap to prescribe an unauthorized peptide (July 2026)

• Victoria Department of Health. Toxicity linked to unapproved peptide product labelled Retatrutide (June 19, 2026)

• The Washington Post. Trump administration paving way for temporary sale of some unapproved peptides (Oct 7, 2026)

• Pink Sheet. US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order (Oct 8, 2026)

• Poder360. Anvisa proíbe canetas de tirzepatida e retatrutida sem registro (Oct 6, 2026, in Portuguese)

---

Disclaimer: This article is for general information and research education only. It summarizes published research, regulatory notices, and news reports and is not medical advice. The peptides mentioned are discussed strictly in a research context. They are not for human consumption, and nothing here recommends or describes their use. Injectable peptides are generally regulated as prescription drugs in Canada; unauthorized products are illegal to sell. Talk to a licensed healthcare professional about any health decision.